Novo Nordisk, a Danish pharmaceutical company, saw its shares rise by 16% after the announcement of positive results from a five-year study on its obesity drug. The study revealed that the drug, marketed as Wegovy, reduces the risk of major adverse cardiovascular events in overweight or obese adults by 20%. Semaglutide, the active component of Wegovy, proved to have a safe and … [Read more...] about Promising Results for Novo Nordisk’s Obesity Drug
Footer
